This chart shows the pharmaceutical companies with the most patents in South Korea. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired. For a global perspective, see the Drug companies wi…
Which pharmaceutical companies have the most drug patents in South Korea? Read Post »
This is an example from the DrugPatentWatch AI Research Assistant, which is available with DrugPatentWatch subscriptions. The DrugPatentWatch AI Research Assistantuses sophisticated AI algorithms to understand and process your questions, delivering pre…
Introduction In the rapidly evolving landscape of pharmaceutical patent disputes in China, injunctive relief has emerged as a critical tool for patent holders. This legal remedy, which aims to halt infringement activities swiftly, plays a pivotal role …
The Double-Edged Sword: Opportunities and Challenges in China’s Patent Litigation System Read Post »
Biotechnology has revolutionized the field of medicine, offering innovative solutions to complex health challenges. From gene editing to personalized treatments,
10 Breakthrough Applications of Biotechnology in Medicine Read Post »
In the high-stakes world of pharmaceuticals, where billions of dollars are at play, securing and maintaining patent protection is paramount. A well-guarded drug patent can spell the difference between a company’s resounding success and its untime…
Safeguarding Your Pharmaceutical Goldmine: Maintaining Your Drug Patent Read Post »
Annual Drug Patent Expirations for OGSIVEO Ogsiveo is a drug marketed by Springworks and is included in one NDA. It is available from one supplier. There are twenty-one patents protecting this drug. This drug has seventy-one patent family members in fo…
Annual Drug Patent Expirations for VEKLURY Veklury is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug. The generic ingredient in VEKLURY is remdesivir…
Annual Drug Patent Expirations for RETEVMO Retevmo is a drug marketed by Loxo Oncol Eli Lilly and is included in two NDAs. It is available from one supplier. There are five patents protecting this drug. This drug has one hundred and twenty-one patent f…
Annual Drug Patent Expirations for PEDMARK Pedmark is a drug marketed by Fennec Pharms Inc and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. This drug has thirty-six patent family members in thi…
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug pat…
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
Get new actionable insights and updates from BiotechBlog
